



Elrexfio in Kuwait

The Kuwait MOH named-patient coordination pathway — indicative 2026

ONCOLOGY · RELAPSED/REFRACTORY MULTIPLE MYELOMA

The clinical situation

Elrexfio (elranatamab-bcmm) is an FDA-approved BCMA×CD3 bispecific antibody from Pfizer for relapsed/refractory multiple myeloma after multiple prior lines. Administered subcutaneously on a step-up schedule to reduce cytokine release syndrome risk, followed by weekly and — in some labeling scenarios — every-two-week maintenance. Step-up is typically inpatient in a haematology unit familiar with CRS and neurotoxicity monitoring; subsequent doses transition to outpatient.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms relapsed/refractory myeloma, line history, and fitness for bispecific therapy.
- 2 Haematology unit confirmed.** A Kuwait tertiary haematology unit with step-up admission capacity and CRS/neurotoxicity monitoring accepts the case.
- 3 Kuwait MOH named-patient application.** Clinical rationale, Civil ID reference, line history, product details, and CRS/neurotoxicity surveillance plan are filed via the importing hospital pharmacy.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; cold-chain shipment with continuous temperature monitoring.
- 5 Arrival, step-up & maintenance dosing.** The hospital pharmacy releases doses for the step-up admission and subsequent outpatient injections.

Indicative economics

Reference US cash-pay range: USD 40,000–48,000 per 4-week maintenance supply; drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

Indicative first-dose timing

7–14 days from a complete Kuwait MOH application to first step-up dose, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and Kuwait MOH review. **Logistics.** Cold-chain, temperature-monitored shipment coordination to your admitting facility. **Concierge case lead.** Named point of contact for family and physician through intake, step-up, and maintenance. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Elrexio × Kuwait first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/elrexio-kuwait.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team